Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Cancer medicine·2026
Same author

Correction: The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.

Breast cancer research and treatment·2026
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same author

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Impact of Baseline Sleep as a Potential Moderator of Weight Loss Intervention in Breast Cancer Survivors: Results From the POWER-Remote Trial.

Obesity (Silver Spring, Md.)·2025
Same journal

Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026
Same journal

Beyond the Scalpel's Reach.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Society.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Hospitals.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions for Providers.

The Surgical clinics of North America·2026
Same journal

Stepwise Solutions-Patients Social Determinants of Health, Health Disparities, and Surgical Equity.

The Surgical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Systemic Therapy for Advanced Soft Tissue Sarcoma.

Jennifer Y Sheng1, Sujana Movva2

  • 1Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

The Surgical Clinics of North America
|August 21, 2016
PubMed
Summary
This summary is machine-generated.

Soft tissue sarcomas (STS) are rare, but advancements in classification and management improve survival. Newer agents show promise in enhancing progression-free survival and overall survival while managing toxicity for advanced STS.

Keywords:
Advanced soft tissue sarcomaChemotherapyNovel therapies

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Related Experiment Videos

Last Updated: Mar 16, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Area of Science:

  • Oncology
  • Medical Oncology
  • Cancer Research

Background:

  • Soft tissue sarcomas (STS) are rare malignancies with up to 10% presenting with distant metastasis.
  • Significant survival improvements have been achieved through enhanced histologic classification and management strategies.

Purpose of the Study:

  • To review the current landscape of systemic therapy for advanced soft tissue sarcoma.
  • To highlight the efficacy and toxicity profiles of both traditional and novel therapeutic agents.

Main Methods:

  • Review of existing literature on soft tissue sarcoma treatments.
  • Analysis of response rates, progression-free survival, and overall survival data for various chemotherapeutic agents.
  • Evaluation of toxicity profiles associated with different treatment modalities.

Main Results:

  • Established agents like doxorubicin and ifosfamide yield objective response rates of 18%–25%.
  • Novel agents including trabectedin, eribulin, aldoxorubicin, and olaratumab demonstrate benefits in progression-free survival, overall survival, or improved toxicity.
  • Ongoing research focuses on optimizing treatment strategies for advanced STS.

Conclusions:

  • Modern management approaches have significantly improved outcomes for soft tissue sarcoma patients.
  • Emerging therapies offer enhanced efficacy and better tolerability, paving the way for personalized treatment.
  • Future research directions include reducing treatment toxicity, tailoring therapy to individual patients, and exploring novel molecular targets.